Centerview Partners

EQS-News: Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Retrieved on: 
Wednesday, April 10, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Sale, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Pharma, Hypoparathyroidism, Fine chemical

Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Key Points: 
  • Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
    The issuer is solely responsible for the content of this announcement.
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • The company led by Thierry Abribat and an exceptional management team has developed innovative therapies for rare endocrine diseases.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

Retrieved on: 
Thursday, March 14, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Hypoparathyroidism, Pharmaceutical industry

LYON, France and CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential milestone payment of $250 million. Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.

Key Points: 
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • We are grateful to the investigators, patients, and patient associations who have supported us to reach these goals,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
  • Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Silver Lake to Take Endeavor Private

Retrieved on: 
Tuesday, April 2, 2024
General Sports, Sports, Finance, General Entertainment, Professional Services, Events, Concerts, Licensing (Sports), Entertainment, MSD, Barclays, Goldman Sachs, TKO, Simpson Thacher & Bartlett, Endeavor Group Holdings, EDR, Royal Bank of Canada, Latham & Watkins, Telecommunications, Committee, Partnership, WWE, Royal Bank, Lexington Partners, Cravath, Swaine & Moore, VWAP, Endeavor (company), Centerview Partners, Kirkland & Ellis, Bank of America, BofA Securities, Sport, Acquisition, RBC Capital Markets, Whitesell, Growth, IMG, BDT, Deutsche Bank, Bank, LLP, Mubadala Investment Company, Martha Plimpton, Music, UFC, Management

Silver Lake believes that when consolidating all of TKO’s value into Endeavor, the combined total enterprise value of $25 billion will make this the largest private equity sponsor public-to-private investment transaction in over a decade, and the largest ever in the media and entertainment sector.

Key Points: 
  • Silver Lake believes that when consolidating all of TKO’s value into Endeavor, the combined total enterprise value of $25 billion will make this the largest private equity sponsor public-to-private investment transaction in over a decade, and the largest ever in the media and entertainment sector.
  • On the unaffected date, the equity value was $8.2 billion, and the premium to be paid by Silver Lake represents $4.6 billion more equity value to all Endeavor stockholders.
  • Ariel Emanuel, CEO of Endeavor, said: "Since 2012, Endeavor’s strategic partnership with Silver Lake and Egon Durban have been central to our evolution into the global sports and entertainment leader we are today.
  • Egon, Stephen, and the broader Silver Lake team have been and will continue to be phenomenal partners in Endeavor’s journey, and we look forward to the road ahead.”
    Stephen Evans, Managing Director of Silver Lake and a Director of Endeavor, said: “The team at Silver Lake is proud of our longstanding partnership with Endeavor, marked by more than $3.5 billion of direct investment across six distinct transactions over 12 years.

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Retrieved on: 
Thursday, March 14, 2024
Professional Services, Health, Other Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Partner, PTHR1, AstraZeneca, Disease, Acromegaly, Patient, Lead, Acquisition, Endocrine disease, Cooley LLP, Investment, Series, Centerview Partners, Alexion, Endocrinology, Hypoparathyroidism

We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.

Key Points: 
  • We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
  • “Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca.
  • Thierry, is a visionary leader and embodies the serial biotech entrepreneurs we partner with,” added Antoine Papiernik, Managing Partner & Chairman of Sofinnova Partners.
  • Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

FiscalNote Announces Fourth Quarter and Full Year 2023 Financial Results; Exceeds Adjusted EBITDA Expectations

Retrieved on: 
Tuesday, March 12, 2024
Professional Services, Data Management, Security, Data Analytics, Technology, Software, Artificial Intelligence, Slate, Software as a service, ARR, Disclosure, LLM, Ernst & Young, Investment, European Parliament, Microsoft, SIAS, Committee, Partnership, Policy, Bell, IRR, Centerview Partners, Microsoft Bing, Organization, Intelligence, Acquisition, AI, Adjustment, Credit, European, GAAP, Public sector, ChatGPT, Government, OpenAI, Growth, FiscalNote, Ratio, Peraton, API, Patent

The Company’s financial results demonstrate FiscalNote’s strong fundamentals including revenue growth of 17% year-over-year in 2023, high gross margins, a diversified blue chip customer base and positive adjusted EBITDA of approximately $3 million(1) in the fourth quarter of 2023.

Key Points: 
  • The Company’s financial results demonstrate FiscalNote’s strong fundamentals including revenue growth of 17% year-over-year in 2023, high gross margins, a diversified blue chip customer base and positive adjusted EBITDA of approximately $3 million(1) in the fourth quarter of 2023.
  • This compares to revenue of $31.4 million and non-GAAP adjusted revenue of $31.5(1) million in the fourth quarter of 2022.
  • Adjusted EBITDA of $3.0 million(1), above the Company’s guidance range announced in November 2023 of approximately $2.5 million.
  • This is an increase of 157% or $8.2 million year-over-year compared to an adjusted EBITDA loss of $5.2 million(1) in the fourth quarter of 2022.

Advance Auto Parts Appoints Three New Independent Directors

Retrieved on: 
Monday, March 11, 2024
Aftermarket, Retail, Automotive, General Automotive, Other Automotive, Specialty, Proskauer Rose, Growth, LLP, Third Point Management, AAP, Saddle Point, O'Reilly Auto Parts, Centerview Partners, Willkie Farr & Gallagher, Advance Auto Parts, Management

Advance Auto Parts, Inc. (NYSE: AAP), a leading automotive aftermarket parts provider in North America that serves both professional installer and do-it-yourself customers, today announced that it has appointed A. Brent Windom, Gregory L. Smith and Thomas W. Seboldt as independent directors to the Advance Auto Parts board, effective immediately.

Key Points: 
  • Advance Auto Parts, Inc. (NYSE: AAP), a leading automotive aftermarket parts provider in North America that serves both professional installer and do-it-yourself customers, today announced that it has appointed A. Brent Windom, Gregory L. Smith and Thomas W. Seboldt as independent directors to the Advance Auto Parts board, effective immediately.
  • “We are pleased to welcome Brent, Greg and Tom to the Advance Auto Parts board,” said Gene Lee, independent chair of the board of directors.
  • At the 2024 annual meeting scheduled for May 22, 2024, 11 director nominees are expected to stand for election to the Advance Auto Parts board, including the three newly appointed directors.
  • Centerview Partners LLC is acting as financial advisor to Advance Auto Parts and Hogan Lovells US LLP is acting as legal counsel.

Blackstone Completes Acquisition of Rover

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Goldman Sachs, Senior, Kirkland & Ellis, Professional corporation, Rover Group, LLP, Centerview Partners, Partnership

SEATTLE, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Rover Group, Inc. (“Rover” or the “Company”), the world’s largest online marketplace for pet care, today announced the completion of its acquisition by private equity funds affiliated with Blackstone (“Blackstone”) in an all-cash transaction valued at approximately $2.3 billion.

Key Points: 
  • SEATTLE, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Rover Group, Inc. (“Rover” or the “Company”), the world’s largest online marketplace for pet care, today announced the completion of its acquisition by private equity funds affiliated with Blackstone (“Blackstone”) in an all-cash transaction valued at approximately $2.3 billion.
  • The transaction was previously announced on November 29, 2023 and was approved by Rover stockholders at Rover’s special meeting of stockholders held on February 22, 2024.
  • With the completion of the acquisition, Rover stockholders are entitled to receive $11.00 in cash for each share of Rover common stock they owned immediately prior to the closing.
  • Evercore acted as lead financial advisor and Moelis & Company LLC also acted as a financial advisor to Blackstone, and Kirkland & Ellis LLP acted as legal counsel to Blackstone.

Leading Proxy Advisor ISS Recommends Shareholders Vote FOR ONLY the Starbucks Director Nominees

Retrieved on: 
Thursday, February 29, 2024
Retail, Communications, Restaurant, Bar, Specialty, Food, Beverage, Public Relations, Investor Relations, Annual general meeting, Institutional Shareholder Services, Lakshman (name), Starbucks, Telephone, Letter, SOC, ISS, Element, History, NOT, Heart, Centerview Partners, Internet, SBUX, Management

Starbucks Corporation (Nasdaq: SBUX) today announced that leading proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that Starbucks shareholders vote on the WHITE proxy card ONLY “FOR” the Starbucks 11 director nominees in connection with the Company's Annual Meeting of Shareholders, which will take place virtually on March 13, 2024, at 10 a.m. PT.

Key Points: 
  • Starbucks Corporation (Nasdaq: SBUX) today announced that leading proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that Starbucks shareholders vote on the WHITE proxy card ONLY “FOR” the Starbucks 11 director nominees in connection with the Company's Annual Meeting of Shareholders, which will take place virtually on March 13, 2024, at 10 a.m. PT.
  • Starbucks is pleased that ISS recognizes the strength of the Starbucks Board and supports the election of all its directors.
  • The company urges shareholders to disregard any materials sent to you by SOC, including any blue proxy card, and NOT to vote using any blue proxy card.
  • Use the WHITE proxy card to vote today ONLY for each of the 11 highly qualified Starbucks director nominees.

Agiliti to Be Taken Private by THL Partners

Retrieved on: 
Monday, February 26, 2024
Medical Supplies, Health, Medical Devices, Practice Management, Health Technology, Managed Care, General Health, Goldman Sachs, THL, Annual report, Committee, Lifting, Thomas H. Lee Partners, Ropes & Gray, Inc., Centerview Partners, Weil, Gotshal & Manges, Partnership

A special committee (the “Special Committee”) of the Agiliti Board of Directors, comprised solely of non-management directors not affiliated or associated with THL and advised by its own independent legal and financial advisors, determined that the proposed transaction is in the best interest of Agiliti and its shareholders (other than THL and its affiliates).

Key Points: 
  • A special committee (the “Special Committee”) of the Agiliti Board of Directors, comprised solely of non-management directors not affiliated or associated with THL and advised by its own independent legal and financial advisors, determined that the proposed transaction is in the best interest of Agiliti and its shareholders (other than THL and its affiliates).
  • Acting upon the unanimous recommendation of the Special Committee, the Agiliti Board of Directors approved the transaction.
  • The transaction has been approved by THL Agiliti LLC in its capacity as the majority shareholder of Agiliti and no other shareholder approval is required.
  • Upon completion of the transaction, Agiliti will become a private company and will no longer be publicly listed or traded on the New York Stock Exchange.

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Retrieved on: 
Monday, February 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acquisition, BMY, Covington & Burling, Growth, RPT, Bristol Myers Squibb, Cooley LLP, Patient, SSTR2, BofA Securities, Tax, Eastern Time Zone, LLP, IND, Centerview Partners, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).
  • With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb.
  • “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.